Gossamer Bio Stock

Gossamer Bio SG&A Expenses

The Selling, General & Administrative Expenses of Gossamer Bio (GOSS) as of Aug 17, 2026 is 37.63 M USD. In the previous year, Selling, General & Administrative Expenses was 36.13 M USD — a change of 4.15% (higher).

SG&A Expenses

37.63 MUSD

YoY

4.15%

Last updated:

Selling, General & Administrative Expenses of Gossamer Bio is 2026 37.63 M USD. Selling, General & Administrative Expenses of Gossamer Bio was 2025 36.13 M USD. It decreases by 4.15% higher compared to the previous year.
Access this data via the Eulerpool API

Gossamer Bio Stock analysis

What does Gossamer Bio do? The company Gossamer Bio Inc. was founded in 2015 by Faheem Hasnain and Sheila Gujrathi. The founders had previously worked at various biotechnology companies and now wanted to start their own company to develop innovative products in the field of immunology. Gossamer Bio is headquartered in San Diego, California and currently employs around 200 people. The company specializes in researching and developing therapeutics for a wide range of diseases, including respiratory diseases, cancer, immunological disorders, and infections. Gossamer Bio's business model is based on identifying promising new drug candidates and subsequently developing therapeutics that have the potential to improve patients' lives. Key pillars of the business model include partnerships with established companies and investors, as well as the rapid and efficient conduct of clinical trials. Gossamer Bio's portfolio includes various pipeline programs in different stages of development. An important focus is on the development of new drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A promising drug candidate in this area is GB001, an inhalation medication that aims to reduce inflammation in the airways. Another important program of Gossamer Bio is the development of therapeutics for the treatment of cancer. The company focuses on the development of drugs that target the body's immune system to specifically fight tumor cells. A promising drug candidate in this area is GB1275, an antibody that specifically targets a protein overexpressed by some types of cancer. In addition to these two focus areas, Gossamer Bio also has programs in the development of therapeutics for the treatment of immunological disorders such as inflammatory bowel disease and rheumatoid arthritis, as well as for the treatment of infections such as COVID-19. Overall, Gossamer Bio has a wide range of promising drug candidates that have the potential to revolutionize the field of immunology and disease management. The company is well positioned to make significant progress in the development of new therapeutics in the coming years and improve the lives of millions of patients worldwide. Gossamer Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gossamer Bio stock

Selling, General & Administrative Expenses of Gossamer Bio is 37.63 M USD in 2026.

Selling, General & Administrative Expenses of Gossamer Bio changed from 36.13 M USD to 37.63 M USD, representing a 4.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Selling, General & Administrative Expenses Gossamer Bio since 2006 – with annual values, charts, and detailed analysis.

SG&A expenses include all non-production costs such as salaries, marketing, rent, and administrative overhead. They are a key component of operating expenses.

Selling, General & Administrative Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Selling, General & Administrative Expenses's Gossamer Bio historically and in real time.

Access this data via the Eulerpool API

Income Statement — Gossamer Bio

All Key Metrics — Gossamer Bio